Mariana Brandão
Research Subjects
Mariana Brandão has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- António Marinho
School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
5 shared publications Fátima Farinha
Medicine Department, Centro Hospitalar do Porto, Porto, Portugal
3 shared publications- Carlos Vasconcelos
School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal
2 shared publications - Isabel Almeida
Internal Medicine, UIC-Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Member of European Reference Network RITA and ReCONNECT, Responsible of the UIC Systemic Sclerosis Cohort, UMIB, ICBAS, Universidade do Porto, Portugal
2 shared publications Alberto Marchi
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italia
1 shared publication- Ana Martins da Silva
Porto University Hospital Center
1 shared publication
Latest Publications
- 21 February 2023
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 76 (9) , 749
Obstrucción medioventricular en miocardiopatía hipertrófica: un vacío de señal
- 21 February 2023
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 76 (9) , 749
Obstrucción medioventricular en miocardiopatía hipertrófica: un vacío de señal
- Open Access
- 4 November 2022
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 60 (5) , 311-317
Sjögren’s syndrome and pregnancy: a Portuguese case-control study
Introduction: Pregnancy in patients with autoimmune disorders is associated with an increased risk of adverse outcomes. Sjögren’s syndrome (SS) is one of the most common among autoimmune diseases. Presently data regarding the impact of SS on obstetric outcomes are scarce and inconclusive. This study aims to evaluate the impact of SS on maternal-fetal and neonatal outcomes compared with pregnancy outcomes in the general population.Material and methods: A retrospective case-control study included 26 pregnancies in SS patients and a healthy control group (CG), followed in a Portuguese tertiary center, between 2015 and 2020. Baseline maternal data were collected, and maternal-fetal and neonatal outcomes were evaluated. Statistical analysis used SPSS 25.0, and a p-value of 0.05 was considered statistically significant.Results: All pregnancies occurred after the diagnosis of SS, with a mean exposure time between diagnosis and pregnancy of 4.92 ±2.78 years. In the SS group, the incidence of ANA, anti-Ro/SSA, and anti-La/SSB antibodies positivity was 80.8%, 61.5%, and 46.2%, respectively. Hydroxychloroquine (HCQ) was used in 57.7%. Miscarriage was significantly higher in the SS group (19.2% vs. 1.8%, p < 0.01). There was a higher prevalence of fetal growth restriction (OR 11.16, 95% CI: 0.96–129.26). Preterm delivery (9.5% vs. 5.6%, p = 0.503) and mean birth weight (2998.16 g vs. 3155.79 g, p = 0.178) did not differ significantly between the groups. In the SS group, admission to the neonatal intensive care unit (NICU) rate was increased (OR 71.67, 95% CI: 3.78–1357.16). Three pregnancies were complicated by congenital heart block (CHB) (14.3% vs. 0%, p = 0.015). In all cases, the diagnosis was performed during second trimester of pregnancy, and betamethasone was administered.Conclusions: Women with SS had a significantly higher incidence of miscarriage, admission to NICU, and CHB than controls. Congenital heart block was the most critical condition that affects the offspring of mothers with SS. Successful pregnancy in the study group was possible with prenatal monitoring and a multidisciplinary approach.
- 4 November 2022
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 60 (5) , 311-317
Open AccessSjögren’s syndrome and pregnancy: a Portuguese case-control study
Introduction: Pregnancy in patients with autoimmune disorders is associated with an increased risk of adverse outcomes. Sjögren’s syndrome (SS) is one of the most common among autoimmune diseases. Presently data regarding the impact of SS on obstetric outcomes are scarce and inconclusive. This study aims to evaluate the impact of SS on maternal-fetal and neonatal outcomes compared with pregnancy outcomes in the general population.Material and methods: A retrospective case-control study included 26 pregnancies in SS patients and a healthy control group (CG), followed in a Portuguese tertiary center, between 2015 and 2020. Baseline maternal data were collected, and maternal-fetal and neonatal outcomes were evaluated. Statistical analysis used SPSS 25.0, and a p-value of 0.05 was considered statistically significant.Results: All pregnancies occurred after the diagnosis of SS, with a mean exposure time between diagnosis and pregnancy of 4.92 ±2.78 years. In the SS group, the incidence of ANA, anti-Ro/SSA, and anti-La/SSB antibodies positivity was 80.8%, 61.5%, and 46.2%, respectively. Hydroxychloroquine (HCQ) was used in 57.7%. Miscarriage was significantly higher in the SS group (19.2% vs. 1.8%, p < 0.01). There was a higher prevalence of fetal growth restriction (OR 11.16, 95% CI: 0.96–129.26). Preterm delivery (9.5% vs. 5.6%, p = 0.503) and mean birth weight (2998.16 g vs. 3155.79 g, p = 0.178) did not differ significantly between the groups. In the SS group, admission to the neonatal intensive care unit (NICU) rate was increased (OR 71.67, 95% CI: 3.78–1357.16). Three pregnancies were complicated by congenital heart block (CHB) (14.3% vs. 0%, p = 0.015). In all cases, the diagnosis was performed during second trimester of pregnancy, and betamethasone was administered.Conclusions: Women with SS had a significantly higher incidence of miscarriage, admission to NICU, and CHB than controls. Congenital heart block was the most critical condition that affects the offspring of mothers with SS. Successful pregnancy in the study group was possible with prenatal monitoring and a multidisciplinary approach.
- Open Access
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1503-1504
AB0406 HUMAN PAPILLOMA VIRUS (HPV) VACCINATION SAFETY IN SYSTEMIC LUPUS ERYTHEMATOSUS COHORT - PORTUGUESE UNIVERSITY HOSPITAL SINGLE-CENTER COHORT STUDY
Background: Cervical cancer is a potentially preventable consequence of Human Papillomavirus (HPV). HPV vaccination is recommended in most countries for all young women, preferentially before sexual activity begins. In Portugal, HPV vaccination is available in either bivalent (genotypes 6, 18) or tetravalent (6, 11, 16 e 18) vaccines. Both have aluminum as an adjuvant, a substance arguably capable of inducing inflammatory adjuvant syndromes. Systemic Lupus Erythematosus (SLE) mostly afflicts women of childbearing age, the very target population for HPV vaccination. There are conflicting reports in the literature regarding both the efficacy and safety of this vaccine in SLE patients. This question is particularly pressing as HPV infection prevalence seems to be increased in SLE patients. Objectives: To analyze the safety of HPV vaccination in a SLE patient cohort followed at a university hospital. Methods: Retrospective single-center (35 year long, 436 SLE patient cohort) review of all female SLE patients’ local and online national records on HPV vaccination and cervical cancer screening. Data on activity (using SLEDAI-2K scoring) and concomitant drug use were reviewed for the two years before and after vaccination date. Results: Of the 463 SLE patients, 420 were women (91%), of which 322 had clinical information about yes/no HPV vaccination. Twenty-seven of the patients (8%) had one of HPV vaccines, but only 13 (4%) had full information on activity before and after vaccination. Mean current age was 33,8 years and a minimum of 8,4 years of follow-up after HPV vaccination. Twenty-there (85%) were vaccinated with the tetravalent vaccine. Pre-vaccination mean SLEDAI score of was 5.9: due to arthritis (n= 5; 38,5%), low complement (n=4; 31%), dsDNA (n=4; 31%); with a medium dose of 10mg prednisolone/day and 265mg/day of hydroxychloroquine. Post-vaccination mean SLEDAI was 5.8: due to arthritis (n=6; 46%), rash (n= 5; 38,5%) and low complement (n=6; 46%); with a medium dose of 8mg prednisolone/day and 288mg/day of hydroxychloroquine. There was not a difference in organ involvement before and after vaccination, but rash was slightly more prevalent after vaccination. Conclusion: In our population, HPV vaccination didn’t significantly change disease activity and organ involvement or mean dose need of prednisolone or hydroxychloroquine. Although it is a small size SLE sample, it suggests that is safe to administer HPV vaccination to SLE patients. References: [1]eularSegal Yahel, Zabludowicz Center for Autoimmune Diseases, Tel Aviv (2017), “HPV and systemic lupus erythematosus: a mosai of potential crossreaction”, SLE Research and Clinical Update, 23 January 2017 [2]Geier David Institute of Chronic Illnesses, USA, (2016), “Quadrivalent human pappilomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database, Environment and Autoimmunity, 13 July 2016 Disclosure of Interests: : None declared
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1503-1504
Open AccessAB0406 HUMAN PAPILLOMA VIRUS (HPV) VACCINATION SAFETY IN SYSTEMIC LUPUS ERYTHEMATOSUS COHORT - PORTUGUESE UNIVERSITY HOSPITAL SINGLE-CENTER COHORT STUDY
Background: Cervical cancer is a potentially preventable consequence of Human Papillomavirus (HPV). HPV vaccination is recommended in most countries for all young women, preferentially before sexual activity begins. In Portugal, HPV vaccination is available in either bivalent (genotypes 6, 18) or tetravalent (6, 11, 16 e 18) vaccines. Both have aluminum as an adjuvant, a substance arguably capable of inducing inflammatory adjuvant syndromes. Systemic Lupus Erythematosus (SLE) mostly afflicts women of childbearing age, the very target population for HPV vaccination. There are conflicting reports in the literature regarding both the efficacy and safety of this vaccine in SLE patients. This question is particularly pressing as HPV infection prevalence seems to be increased in SLE patients. Objectives: To analyze the safety of HPV vaccination in a SLE patient cohort followed at a university hospital. Methods: Retrospective single-center (35 year long, 436 SLE patient cohort) review of all female SLE patients’ local and online national records on HPV vaccination and cervical cancer screening. Data on activity (using SLEDAI-2K scoring) and concomitant drug use were reviewed for the two years before and after vaccination date. Results: Of the 463 SLE patients, 420 were women (91%), of which 322 had clinical information about yes/no HPV vaccination. Twenty-seven of the patients (8%) had one of HPV vaccines, but only 13 (4%) had full information on activity before and after vaccination. Mean current age was 33,8 years and a minimum of 8,4 years of follow-up after HPV vaccination. Twenty-there (85%) were vaccinated with the tetravalent vaccine. Pre-vaccination mean SLEDAI score of was 5.9: due to arthritis (n= 5; 38,5%), low complement (n=4; 31%), dsDNA (n=4; 31%); with a medium dose of 10mg prednisolone/day and 265mg/day of hydroxychloroquine. Post-vaccination mean SLEDAI was 5.8: due to arthritis (n=6; 46%), rash (n= 5; 38,5%) and low complement (n=6; 46%); with a medium dose of 8mg prednisolone/day and 288mg/day of hydroxychloroquine. There was not a difference in organ involvement before and after vaccination, but rash was slightly more prevalent after vaccination. Conclusion: In our population, HPV vaccination didn’t significantly change disease activity and organ involvement or mean dose need of prednisolone or hydroxychloroquine. Although it is a small size SLE sample, it suggests that is safe to administer HPV vaccination to SLE patients. References: [1]eularSegal Yahel, Zabludowicz Center for Autoimmune Diseases, Tel Aviv (2017), “HPV and systemic lupus erythematosus: a mosai of potential crossreaction”, SLE Research and Clinical Update, 23 January 2017 [2]Geier David Institute of Chronic Illnesses, USA, (2016), “Quadrivalent human pappilomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database, Environment and Autoimmunity, 13 July 2016 Disclosure of Interests: : None declared
- 6 February 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Tuberculous osteomyelitis of the wrist presenting as a monoarthritis syndrome
Osteoarticular tuberculosis is the third most frequent location of tuberculosis after the lung and lymph nodes, accounting for approximately 10%–20% of all cases of extrapulmonary disease. Tuberculosis of the hand and wrist is the rarest osteoarticular location after the shoulder. The authors report the case of a 50-year-old woman without medical history who was diagnosed with isolated tuberculosis of the wrist presenting as monarthritis. The diagnosis was confirmed by histopathological and microbiological examination. Late stages of osteomyelitis are even rarer without any predisposing factors such as immunosuppression. This case underlines the importance of including tuberculosis in the differential diagnosis of monoarthritic syndromes to prevent delayed initiation of therapy and consequent complications and bone damage.
- 6 February 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Tuberculous osteomyelitis of the wrist presenting as a monoarthritis syndrome
Osteoarticular tuberculosis is the third most frequent location of tuberculosis after the lung and lymph nodes, accounting for approximately 10%–20% of all cases of extrapulmonary disease. Tuberculosis of the hand and wrist is the rarest osteoarticular location after the shoulder. The authors report the case of a 50-year-old woman without medical history who was diagnosed with isolated tuberculosis of the wrist presenting as monarthritis. The diagnosis was confirmed by histopathological and microbiological examination. Late stages of osteomyelitis are even rarer without any predisposing factors such as immunosuppression. This case underlines the importance of including tuberculosis in the differential diagnosis of monoarthritic syndromes to prevent delayed initiation of therapy and consequent complications and bone damage.
- Open Access
- 1 January 2013
- Published by Editora Cubo in Cadernos de Terapia Ocupacional da UFSCar
- Vol. 21 (3) , 471-478
Mobilidade sobre rodas: a percepção de pais de crianças com paralisia cerebral
Children with cerebral palsy (CP) often use mobility devices as facilitators of their functionality and independence, and these devices may have a positive impact on their caregivers’ quality of life. Considering a family-centered approach, parents assume a decisive role in different stages of the therapeutic process, guiding \ud several actions of the rehabilitation professionals during the search, development and/or adaptation of equipment \ud that meet the specific needs of customers. The aim of this research was to understand the perceptions of parents \ud of children with CP on the use of the wheelchair in the daily routines of their children. This qualitative study used semi-structured interviews with 16 parents of CP children who were wheelchair users assisted at ‘Associação Mineira de Reabilitação’. Content analysis grounded the categorization of themes that emerged from the interviews. The results expressed in themes such as “The look on the daily routine” and “The look on the equipment” pointed \ud out characteristics related to the benefits of the use of the wheelchair in promoting child participation at home, at \ud school, and in community environments, as well as different features of wheelchairs that facilitate or hamper their \ud use in children’s daily routine.\u
- 1 January 2013
- Published by Editora Cubo in Cadernos de Terapia Ocupacional da UFSCar
- Vol. 21 (3) , 471-478
Open AccessMobilidade sobre rodas: a percepção de pais de crianças com paralisia cerebral
Children with cerebral palsy (CP) often use mobility devices as facilitators of their functionality and independence, and these devices may have a positive impact on their caregivers’ quality of life. Considering a family-centered approach, parents assume a decisive role in different stages of the therapeutic process, guiding \ud several actions of the rehabilitation professionals during the search, development and/or adaptation of equipment \ud that meet the specific needs of customers. The aim of this research was to understand the perceptions of parents \ud of children with CP on the use of the wheelchair in the daily routines of their children. This qualitative study used semi-structured interviews with 16 parents of CP children who were wheelchair users assisted at ‘Associação Mineira de Reabilitação’. Content analysis grounded the categorization of themes that emerged from the interviews. The results expressed in themes such as “The look on the daily routine” and “The look on the equipment” pointed \ud out characteristics related to the benefits of the use of the wheelchair in promoting child participation at home, at \ud school, and in community environments, as well as different features of wheelchairs that facilitate or hamper their \ud use in children’s daily routine.\u
- 7 June 2012
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 43 (3) , 302-307
Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection caused by the reactivation of JC virus and occurs in patients with severe primary or secondary immunosuppression. Recently, PML is becoming relevant in autoimmune disorders, particularly in patients treated with biologic agents. However, systemic lupus erythematosus (SLE) appears to be associated with susceptibility to PML that cannot be entirely explained by the immunosuppressive therapy. The authors present two patients with the diagnosis of SLE and PML: One had a heavy immunosuppressive therapy history, and the other had never experienced biologic or cytotoxic therapeutics. Both patients had a profound T-CD4+ lymphopenia during their clinical history. These two cases emphasize the importance of CD4+ lymphopenia in SLE patients with and without immunosuppressors regarding opportunistic infections.
- 7 June 2012
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 43 (3) , 302-307
Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection caused by the reactivation of JC virus and occurs in patients with severe primary or secondary immunosuppression. Recently, PML is becoming relevant in autoimmune disorders, particularly in patients treated with biologic agents. However, systemic lupus erythematosus (SLE) appears to be associated with susceptibility to PML that cannot be entirely explained by the immunosuppressive therapy. The authors present two patients with the diagnosis of SLE and PML: One had a heavy immunosuppressive therapy history, and the other had never experienced biologic or cytotoxic therapeutics. Both patients had a profound T-CD4+ lymphopenia during their clinical history. These two cases emphasize the importance of CD4+ lymphopenia in SLE patients with and without immunosuppressors regarding opportunistic infections.
- Open Access
- 1 January 2012
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 4 (2) , 138-144-44
Hypertrophic Cranial Pachymeningitis and Skull Base Osteomyelitis by Pseudomonas Aeruginosa: Case Report and Review of the Literature
Hypertrophic cranial pachymeningitis (HCP) is an uncommon disorder characterized by localized or diffuse thickening of the dura mater, and it usually presents with multiple cranial neurophaties. It has been associated with a variety of inflammatory, infectious, traumatic, toxic and neoplasic diseases, when no specific cause is found the process is called idiopathic. The infectious cases occur in patients under systemic immunosuppression, which have an evident contiguous source or those who have undergone neurosurgical procedures. We describe a case of a 62-year-old immunosuppressed woman with diabetes and rheumatoid arthritis, which had HCP and osteomyelitis of the skull base caused by pseudomonas aeruginosa, presenting with headache and diplopia. We believe this is the second documented case of pachymeningitis secondary to this microorganism. As a multifactorial disease, it is essencial to determine the specific causative agent of HCP before making treatment decisions, and great care is needed with immunocompromised patients. doi:10.4021/jocmr777w
- 1 January 2012
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 4 (2) , 138-144-44
Open AccessHypertrophic Cranial Pachymeningitis and Skull Base Osteomyelitis by Pseudomonas Aeruginosa: Case Report and Review of the Literature
Hypertrophic cranial pachymeningitis (HCP) is an uncommon disorder characterized by localized or diffuse thickening of the dura mater, and it usually presents with multiple cranial neurophaties. It has been associated with a variety of inflammatory, infectious, traumatic, toxic and neoplasic diseases, when no specific cause is found the process is called idiopathic. The infectious cases occur in patients under systemic immunosuppression, which have an evident contiguous source or those who have undergone neurosurgical procedures. We describe a case of a 62-year-old immunosuppressed woman with diabetes and rheumatoid arthritis, which had HCP and osteomyelitis of the skull base caused by pseudomonas aeruginosa, presenting with headache and diplopia. We believe this is the second documented case of pachymeningitis secondary to this microorganism. As a multifactorial disease, it is essencial to determine the specific causative agent of HCP before making treatment decisions, and great care is needed with immunocompromised patients. doi:10.4021/jocmr777w
- 30 September 2011
- Published by Elsevier in Autoimmunity Reviews
- Vol. 10 (11) , 720-724
Idiopathic inflammatory myopathies: Definition and management of refractory disease
- 30 September 2011
- Published by Elsevier in Autoimmunity Reviews
- Vol. 10 (11) , 720-724
Idiopathic inflammatory myopathies: Definition and management of refractory disease
- Open Access
- 1 January 2011
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 2 (4) , 151-155
Hyper-IgE Syndrome: Report of Three Cases and Review of Literature
The hyper-immunoglobulin E syndrome (HIES) is a rare primary immunodeficiency disorder characterized by high serum levels of immunoglobulin E (IgE), recurrent skin and lung infections, chronic dermatitis and a variety of connective tissue and skeletal abnormalities. The bacteria that commonly infect these patients are Staphylococcus aureus and Haemophilus influenzae. These patients share some characteristic facial appearance and many oral manifestations. Therapy should include prolonged antibiotic therapy. We report the clinical picture of three patients that presented recurrent infections and different outcomes, and then we describe and compare with our patients the clinical, laboratory and therapeutic aspects of HIES. doi:10.4021/jmc213w
- 1 January 2011
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 2 (4) , 151-155
Open AccessHyper-IgE Syndrome: Report of Three Cases and Review of Literature
The hyper-immunoglobulin E syndrome (HIES) is a rare primary immunodeficiency disorder characterized by high serum levels of immunoglobulin E (IgE), recurrent skin and lung infections, chronic dermatitis and a variety of connective tissue and skeletal abnormalities. The bacteria that commonly infect these patients are Staphylococcus aureus and Haemophilus influenzae. These patients share some characteristic facial appearance and many oral manifestations. Therapy should include prolonged antibiotic therapy. We report the clinical picture of three patients that presented recurrent infections and different outcomes, and then we describe and compare with our patients the clinical, laboratory and therapeutic aspects of HIES. doi:10.4021/jmc213w
- 1 January 2005
- Vol. 90 (1) , 31-7
The soluble transferrin receptor as a marker of iron homeostasis in normal subjects and in HFE-related hemochromatosis.
The soluble transferrin receptor (sTfR) is a clinical marker of erythropoietic activity, also used in the diagnosis of iron deficiency. In the present paper we explore the meaning of this parameter in normal physiological conditions of iron homeostasis and in the setting of iron overload due to hereditary hemochromatosis (HH). Reference values for sTfR were established in a population of 42 apparently healthy subjects, analyzed in relation to other hematologic parameters, namely, hemoglobin (Hb), mean corpuscular volume (MCV), transferrin saturation (TfSat) and serum ferritin. The same analysis was done in a group of 45 patients with HH who were homozygous for the C282Y mutation of HFE and had a wide range of TfSat values. In addition, individual serial profiles were analyzed in three patients. In normal subjects circulating sTfR correlated significantly with the TfSat level, reflecting the systemic effect of iron availability on the erythropoietic activity in a normal physiological steady state. A TfSat of 25% appeared as a threshold value, below which there was a progressive increase in sTfR; this increase in sTfR occurred concomitantly with a decrease in Hb, MCV and serum ferritin. In HH patients the up-regulation of sTfR started at TfSat values as high as 50%. The fact that sTfR up-regulation started at higher TfSat values in HH patients suggests that the recognition of systemic iron available for erythropoiesis is altered in this condition. Based on these results, a new hypothesis is advanced, proposing that the HFE protein in involved as a sensor of systemic iron availability, via the soluble transferrin receptor.
- 1 January 2005
- Vol. 90 (1) , 31-7
The soluble transferrin receptor as a marker of iron homeostasis in normal subjects and in HFE-related hemochromatosis.
The soluble transferrin receptor (sTfR) is a clinical marker of erythropoietic activity, also used in the diagnosis of iron deficiency. In the present paper we explore the meaning of this parameter in normal physiological conditions of iron homeostasis and in the setting of iron overload due to hereditary hemochromatosis (HH). Reference values for sTfR were established in a population of 42 apparently healthy subjects, analyzed in relation to other hematologic parameters, namely, hemoglobin (Hb), mean corpuscular volume (MCV), transferrin saturation (TfSat) and serum ferritin. The same analysis was done in a group of 45 patients with HH who were homozygous for the C282Y mutation of HFE and had a wide range of TfSat values. In addition, individual serial profiles were analyzed in three patients. In normal subjects circulating sTfR correlated significantly with the TfSat level, reflecting the systemic effect of iron availability on the erythropoietic activity in a normal physiological steady state. A TfSat of 25% appeared as a threshold value, below which there was a progressive increase in sTfR; this increase in sTfR occurred concomitantly with a decrease in Hb, MCV and serum ferritin. In HH patients the up-regulation of sTfR started at TfSat values as high as 50%. The fact that sTfR up-regulation started at higher TfSat values in HH patients suggests that the recognition of systemic iron available for erythropoiesis is altered in this condition. Based on these results, a new hypothesis is advanced, proposing that the HFE protein in involved as a sensor of systemic iron availability, via the soluble transferrin receptor.